Next Article in Journal
Nasopharyngeal Non-Intestinal-Type Adenocarcinoma: A Case Report and Updated Review of the Literature
Previous Article in Journal
Guideline for Radiotherapy with Curative Intent in Patients with Early-Stage Medically Inoperable Non-Small-Cell Lung Cancer
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Open AccessArticle

Examining the Medical Resource Utilization and Costs of Relapsed and Refractory Chronic Lymphocytic Leukemia in Ontario

1
Health Outcomes and PharmacoEconomics (hope) Research Centre, Sunnybrook Research Institute, Toronto, ON, Canada
2
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
3
Department of Medicine, Division of Hematology, University of Toronto, Toronto, ON, Canada
4
Juravinski Cancer Centre, Hamilton Health Sciences Centre, Hamilton, ON, Canada
5
Department of Oncology, Division of Malignant Hematology, McMaster University, Hamilton, ON, Canada
6
Janssen Inc., Toronto, ON, Canada
7
Department of Pharmacology, University of Toronto, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2017, 24(1), 50-54; https://doi.org/10.3747/co.24.3182
Received: 8 November 2016 / Revised: 9 December 2016 / Accepted: 10 January 2017 / Published: 1 February 2017
Purpose: The purpose of the present study was to collect medical resource utilization data and costs in Ontario for the management of patients with relapsed or refractory chronic lymphocytic lymphoma (cll) who have undergone at least 1 treatment course and have been stratified by Rai staging. Methods: This retrospective longitudinal cohort study, conducted by chart review, analyzed anonymized patient records from two cancer centres in Ontario. Comprehensive records of 86 patients meeting the inclusion criteria were used to obtain resource utilization, which, multiplied by unit costs, were used to determine overall and mean costs. Descriptive statistics are presented for patient demographics, medical resource utilization, and costing data. Results: The total cost for the cohort was $2.2 million over a mean follow-up period of 4.7 years. The mean total cost per patient (regardless of follow-up) was $25,736. In terms of Rai staging, overall mean costs were highest for stage iv patients. Almost 50% of the total cost was attributable to cll treatments, among which fludarabine-based treatments had the highest utilization. Conclusions: For this Canadian cll cohort, medical resource utilization and costs were determined to be $2.2 million, with cll treatments accounting for about half the cost. Costs generally increased with Rai stage.
Keywords: chronic lymphocytic leukemia; utilization; costs; Canada chronic lymphocytic leukemia; utilization; costs; Canada
MDPI and ACS Style

Hassan, S.; Seung, S.J.; Cheung, M.C.; Fraser, G.; Kuriakose, B.; Trambitas, C.; Mittmann, N. Examining the Medical Resource Utilization and Costs of Relapsed and Refractory Chronic Lymphocytic Leukemia in Ontario. Curr. Oncol. 2017, 24, 50-54. https://doi.org/10.3747/co.24.3182

AMA Style

Hassan S, Seung SJ, Cheung MC, Fraser G, Kuriakose B, Trambitas C, Mittmann N. Examining the Medical Resource Utilization and Costs of Relapsed and Refractory Chronic Lymphocytic Leukemia in Ontario. Current Oncology. 2017; 24(1):50-54. https://doi.org/10.3747/co.24.3182

Chicago/Turabian Style

Hassan, S.; Seung, S.J.; Cheung, M.C.; Fraser, G.; Kuriakose, B.; Trambitas, C.; Mittmann, N. 2017. "Examining the Medical Resource Utilization and Costs of Relapsed and Refractory Chronic Lymphocytic Leukemia in Ontario" Curr. Oncol. 24, no. 1: 50-54. https://doi.org/10.3747/co.24.3182

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop